Contents: Health Policy in PracticeWomen's Health, Pregnancy, and the U.S. Food and Drug AdministrationGee, Rebekah E. MD, MPH; Wood, Susan F. PhD; Schubert, Kathryn G. MPPAuthor Information Departments of Health Policy and Management and Obstetrics and Gynecology, Louisiana State University, Schools of Public Health and Medicine, New Orleans, Louisiana; the Jacobs Institute of Women's Health, the Department of Health Policy, School of Public Health and Health Services, George Washington University, and Cavarocchi|Ruscio|Dennis Associates, LLC, Washington, DC. Corresponding author: Rebekah E. Gee, MD, MPH, 2020 Gravier Street, New Orleans, LA 70112; e-mail: firstname.lastname@example.org. The authors thank the members of the Health Policy Committee of the Society for Maternal-Fetal Medicine (SMFM) for their significant contributions to this manuscript. Members of the SMFM Health Policy Committee with editing contributions are: Joanne Armstrong, Suneet P. Chauhan, Judette Louis, George R. Saade, and Sindhu Srinivas. Financial Disclosure The authors did not report any potential conflicts of interest. Obstetrics & Gynecology: January 2014 - Volume 123 - Issue 1 - p 161-165 doi: 10.1097/AOG.0000000000000063 Buy Metrics Drugs and devices intended for women have a controversial history that may hamper pharmaceutical, biologic, and device research specific to women. © 2014 by The American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.